Related Experiment Video
Updated: May 10, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
DICCA-DTA: Diffusion and Contextualized Capsule Attention guided Factorized Cross-Pooling for Drug-Target Affinity
1Department of Information Science and Technology, College of Engineering Guindy, Chennai, India.
The DICCA-DTA framework enhances drug discovery by improving drug-target affinity prediction. It accurately models complex interactions and identifies critical binding sites for better accuracy and interpretability.
Area of Science:
- Computational chemistry
- Drug discovery
- Bioinformatics
Background:
- Drug-Target Affinity (DTA) prediction is vital for drug discovery.
- Current deep learning methods face challenges in molecular graph representation and interaction modeling.
- Accurate DTA prediction requires effective feature extraction and interaction prioritization.
Purpose of the Study:
- To introduce the DICCA-DTA framework for improved DTA prediction.
- To address limitations in molecular information propagation and interaction modeling.
- To enhance the accuracy and interpretability of drug-target interaction predictions.
Main Methods:
- Utilized a Diffused Isomorphic Network (DIN) for comprehensive drug feature extraction.
- Employed a Contextualized Capsule Attention Network (CCAN) for protein sequence characteristic modeling.
- Implemented an attention-guided Factorized Cross-Pooling (FCP) mechanism for refined interaction modeling and explainable attention maps.
Main Results:
- DICCA-DTA demonstrated superior performance across Davis, KIBA, Metz, and BindingDB datasets.
- The framework accurately models complex drug-protein binding site interactions.
- Explainable attention maps provided transparent insights into critical interactions.
Conclusions:
- The DICCA-DTA framework significantly advances DTA prediction accuracy and interpretability.
- It offers a robust approach for identifying key drug-protein affinities.
- The framework has the potential to accelerate drug discovery and repurposing efforts.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
Related Concept Videos
Drug Discovery: Overview
Pore Transport and Ion-Pair Transport
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...